Shaff, who is currently chief operating and Financial officer, succeeds Roger J. Pomerantz, M.D. Shaff has also joined Seres' board of directors and will continue to serve as Seres' principal financial officer on an interim basis.
Pomerantz will continue as chairman of Seres' board of directors.
Shaff has served as Seres' chief financial officer, executive vice president and treasurer since November 2014, and in January 2018, he was appointed to the additional role of chief operating officer.
He also serves on the board of directors for Sigilon Therapeutics and has extensive experience in the biotechnology field, having worked at Momenta Pharmaceuticals and Genzyme Corp., where he was vice president of Finance for the Personalized Genetic Health division.
Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.
The company's lead programme, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection.
SER-287 is currently being evaluated in a Phase 2B study in patients with active mild-to-moderate ulcerative colitis.
Seres is advancing SER-401 to augment the efficacy of immuno-oncology treatment.
In addition, the company has several other microbiome therapeutic candidates in preclinical development for various serious diseases.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval